Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (323)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03481231 | In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma(IMMUNOGLIO) | completed | — | 160 | Centre Georges Francois LeclercOTHER | 2 | Feb 17, 2025 | clinicaltrials |
| NCT05140902 | Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom | completed | N/A | 12 | University of Alabama at BirminghamOTHER | 1 | Feb 14, 2025 |
| clinicaltrials |
| NCT03443128 | Vinorelbine for Recurrent ALCL-2017 | completed | Phase 2 | 20 | Children's Cancer Group, ChinaNETWORK | 1 | Feb 13, 2025 | clinicaltrials |
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04774068 | Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | completed | Phase 1 | 5 | Walter HanelOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT05296122 | Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions | completed | N/A | 14 | Clinical Laserthermia Systems ABINDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | completed | Phase 1 | 59 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02465268 | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme(ATTAC-II) | completed | Phase 2 | 175 | University of FloridaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04842513 | Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma(GLIO-XS15) | completed | Phase 1 | 15 | University Hospital TuebingenOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT01849146 | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | completed | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04280848 | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma(UCPVax-Glio) | completed | Phase 2 | 67 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT01752491 | A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme | completed | Phase 1 | 13 | Joseph J. Cullen, MD, FACSOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05015543 | Physical Training in Glioblastoma Patients During Cytotoxic Therapy(MMH) | completed | N/A | 54 | University Hospital MuensterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01464177 | Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme(GBM Hypo RT) | completed | Phase 2 | 40 | Andre Tsin Chih ChenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04726397 | UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial(UNITED) | completed | N/A | 108 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT03232424 | NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Hackensack Meridian HealthOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05062772 | Brain Tumor Intraoperative Ultrasound Database(BraTioUS-DB) | completed | — | 150 | Hospital del Rio HortegaOTHER | 5 | Nov 15, 2024 | clinicaltrials |
| NCT03865355 | Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients | completed | — | 50 | Novosibirsk State UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03732352 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | completed | Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04845919 | Sonodynamic Therapy With ExAblate System in Glioblastoma Patients(Sonic ALA) | completed | Phase 2 | 5 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT03922984 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma | completed | N/A | 43 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04304300 | Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes(RIGEL) | completed | — | 80 | Erasmus Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03926507 | F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery | completed | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01811992 | Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma | completed | Phase 1 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03234595 | A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 22 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03278249 | Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma | completed | N/A | 12 | University of CincinnatiOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03661723 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06600399 | Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma(PSMA，ASL，PET) | completed | — | 26 | Lanzhou University Second HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03995706 | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | completed | Early Phase 1 | 26 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT01204684 | Dendritic Cell Vaccine for Patients With Brain Tumors | completed | Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04013672 | Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | completed | Phase 2 | 41 | David PeereboomOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01793233 | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | completed | — | 203 | Children's Oncology GroupNETWORK | 2 | Aug 26, 2024 | clinicaltrials |
| NCT01923922 | CT Perfusion in the Prognostication of Cerebral High Grade Glioma | completed | N/A | 48 | Nova Scotia Health AuthorityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06562621 | Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 38 | Beijing Neurosurgical InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04492163 | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM | completed | Phase 2 | 25 | NovoCure GmbHINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT05977738 | Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin(ReDiReCCT-Pita) | completed | Early Phase 1 | 12 | C.DirvenOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06538428 | Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients | completed | — | 78 | Ain Shams UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06038604 | Glioblastoma Psychosocial Support Program | completed | N/A | 11 | Duke UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03493932 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | completed | Phase 1 | 21 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02441322 | Evaluating Therapeutic Response to Novo-TTF | completed | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT01817751 | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 47 | Virginia Commonwealth UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2025source: clinicaltrials